Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Hematology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TSPAN33 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TSPAN33 Extracellular Loop 2 (EC2/LEL)-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View TSPAN33 Products |
| Gene Delivery | TSPAN33 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and conformational assays. |
View TSPAN33 Products |
| Benchmark Ab | Anti-TSPAN33 Recombinant Antibody Recombinant positive control for flow cytometry and binding assays. |
View TSPAN33 Products |
| Validator | TSPAN33 siRNA Set For knockdown verification in functional assays. |
View TSPAN33 Products |
| Related Target A | ADAM10 Key metalloprotease regulated by TSPAN33; crucial for Notch signaling and shedding assays. |
View ADAM10 Products |
| Related Target B | TSPAN8 Homologous tetraspanin; required for selectivity and off-target counter-screening. |
View TSPAN8 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of Multi-pass Membrane Protein | Lentiviral transduction systems preserve native 4-transmembrane folding on host cell membranes. |
| Subfamily Selectivity (TSPAN Cross-reactivity) | High-purity recombinant EC2 domains of related tetraspanins (TSPAN8, CD81) for counter-screening. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies included for assay validation. |
| False Positives | Validated siRNA sets included for target-specific knockdown verification. |
Live TSPAN33 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TSPAN33 therapeutics is intensifying, with major players shifting focus from traditional mAbs to targeted cell therapies and antibody-drug conjugates (ADCs). As an emerging tetraspanin family target with restricted normal tissue expression and high upregulation in specific B-cell malignancies and solid tumors, TSPAN33 represents a highly selective therapeutic window. The next wave of R&D is targeting its interaction with metalloproteases like ADAM10 to disrupt tumor microenvironment signaling.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Biotech Innovators | B-cell Malignancies, Erythroleukemia | Native conformation binding (Need Lentivirus for Stable Cell Lines) |
| Antibody-Drug Conjugate (ADC) | Oncology Biopharma | Solid Tumors, Melanoma | Internalization Assay (Need high-purity EC2-Fc fusion proteins) |
| CAR-T / Cell Therapy | Cell Therapy Specialists | Refractory Hematological Tumors | Flow Cytometry validation (Need Lentivirus-driven target overexpression) |